Accelerate to discover

Back to filter

Related topics

Download today your IsoPlexis e-book: understanding immune Cell Function In Cancer

IsoPlexis

Dec 1, 2021

Understanding complex immune-cancer interactions is critical to identifying therapeutic targets, devising novel avenues...

IsoPlexis technology: accelerating decisions in immunotherapy with predictive single-cell response

IsoPlexis

Nov 25, 2021

The IsoLight is a hub for comprehensive functional profiling of each cell type across a large assay menu of single-cell...

Extensive assessment of Cytokine production on the NovoCyte Penteon flow cytometer

Agilent technologies

Nov 23, 2021

Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...

Introducing isoLight system - Automated Cellular Proteomics hub

IsoPlexis

Nov 4, 2021

The IsoLight is a hub for comprehensive functional profiling of each cell type across a large assay menu of single-cell...

Jan 26, 2022

Introducing Cytek NEW 25-Color Immunoprofiling Assay & Kit!

Cytek Biosciences

Oct 25, 2021

To unleash the power of the Cytek full spectrum cytometry system, Cytek scientists designed and developed the 25-Color...

X-ray-virus-inactivation

Precision X-Ray

Oct 20, 2021

Ionizing radiation approaches are effective but use of radioactive radioisotopic elements have become difficult to...

Duke uses XRAD 225 CX to test radiosensitivity hypothesis

Precision X-Ray

Oct 18, 2021

Image guided radiotherapy in a preclinical setting couldn’t be more useful than the treatment of brain tumors, where...

Jan 26, 2022

Curiox webinar: Laminar Wash enables single-cell multiomics and cell hashing

Curiox

Oct 11, 2021

Professor Mats Bemark’s lab at the University of Gothenburg in Sweden studies how the immune system responds to...

Show all topics (10)

Better antibody discovery using IntelliCyt’s iQue Screener

May 18, 2016

With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.

Read more

 

Scientific paper
Product news

Related technologies: HTP Screening

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

IntelliCyt

IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey